Holen Sie sich die Stockscreener-App
1.78
8.54%
0.14
Handel nachbörslich:
1.87
0.09
+5.06%
Werewolf Therapeutics Inc Aktie (HOWL) Neueste Nachrichten
Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference - The Manila Times
Werewolf Therapeutics stock hits 52-week low at $1.62 - Investing.com India
Werewolf Therapeutics stock hits 52-week low at $1.62 By Investing.com - Investing.com Canada
Werewolf Therapeutics stock holds buy rating amid investor concerns over cytokine therapies By Investing.com - Investing.com Canada
Werewolf Therapeutics' (HOWL) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Werewolf Therapeutics (NASDAQ:HOWL) Has Debt But No Earnings; Should You Worry? - Simply Wall St
Equities Analysts Set Expectations for HOWL FY2024 Earnings - MarketBeat
Werewolf Therapeutics' SWOT analysis: oncology biotech's stock potential amid clinical progress - Investing.com Australia
What is HC Wainwright's Forecast for HOWL Q1 Earnings? - MarketBeat
Werewolf Therapeutics reports promising trial data for cancer drug By Investing.com - Investing.com South Africa
Werewolf Therapeutics Inc (HOWL) Quarterly 10-Q Report - Quartz
Werewolf Therapeutics reports promising trial data for cancer drug - Investing.com
Werewolf Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
Werewolf Therapeutics Presents Preclinical and Clinical - GlobeNewswire
Werewolf's WTX-330 Shows Promise in Phase 1 Trial: Melanoma Patient Responds to Novel IL-12 Therapy | HOWL Stock News - StockTitan
Werewolf Therapeutics Reports Breakthrough Cancer Trial Results Despite $16.7M Loss | HOWL Stock News - StockTitan
Werewolf Therapeutics announces IL-10 Indukine development candidate for inflammatory bowel disease - BioWorld Online
Werewolf Therapeutics expands pipeline with new IBD candidate By Investing.com - Investing.com South Africa
Werewolf Therapeutics expands pipeline with new IBD candidate - Investing.com
Werewolf Therapeutics Announces Promising New Development Candidate, WTX-921, a first-of-its-kind IL-10 INDUKINE™ Molecule for Inflammatory Diseases - The Manila Times
Werewolf Therapeutics Announces Promising New Development - GlobeNewswire
WisdomTree Inc (NYSE: WT): Blank Check On Growth? - Stocks Register
Werewolf To Provide Clinical Update On WTX-330 - RTTNews
Werewolf Therapeutics Inc (NASDAQ: HOWL) Could Pass $12 In One Year Stock Forecast - Stocks Register
Social Security Just Released the 2025 COLA. Here's What It Means for Those Receiving Spousal Benefits. - Yahoo! Voices
Could Buying Apple Stock Today Set You Up for Life? - Yahoo! Voices
Is Summit Therapeutics Inc. (SMMT) the Best QQQ Stock to Buy According to Analysts? - Yahoo Finance
Lyft is working on a ‘service animal opt-in feature’ for passengers - Yahoo! Voices
Hammond packaging facility to get $35M upgrade - Yahoo! Voices
2 Game-Changing Artificial Intelligence (AI) Stocks to Buy Right Now (Hint: Not Nvidia) - Yahoo! Voices
Poland’s stunning success should be discomforting for Britain - Yahoo! Voices
Every UPS Investor Should Keep an Eye on This Number - Yahoo! Voices
Billionaire Philippe Laffont Just Increased His Position by 139% in This Data Center Opportunity (Hint: It's Not Nvidia) - Yahoo! Voices
We're Not Very Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Rate - Yahoo Finance
ProQR Therapeutics (NASDAQ:PRQR) shareholder returns have been solid, earning 231% in 1 year - Yahoo Finance
Bank of America Predicts up to ~390% Surge for These 2 ‘Strong Buy’ Stocks - Yahoo Finance
Cut the state to get growing - Yahoo! Voices
‘It’s huge’: Striking Boeing workers near deal - Yahoo! Voices
National Association of Black Accountants’ St. Louis Chapter honors 50 years of community impact - Yahoo! Voices
Voya Financial Reports $341 Billion AUM Milestone - Yahoo Finance
Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance
mRNA licensing agreements surge 800% amid GSK lawsuits - Yahoo Finance
State Street Corp's Strategic Reduction in Viridian Therapeutics Inc - Yahoo Finance
State Street Corp's Strategic Reduction in Viking Therapeutics Holdings - Yahoo Finance
Nvidia to be the first company to hit $4T market cap: Lumida CEO - Yahoo Finance
LGT incorporates its Barcelona digital hub - Yahoo News
Amicus Therapeutics (FOLD) Stock Jumps 14.0%: Will It Continue to Soar? - Yahoo Finance
Millennium Management LLC's Strategic Reduction in Esperion Therapeutics Inc Holdings - Yahoo Finance
NantHealth (NASDAQ:NH) Coverage Initiated by Analysts at StockNews.com - Defense World
StockNews.com Downgrades Nomad Foods (NYSE:NOMD) to Hold - Defense World
Microsoft said it lost weeks of security logs for its customers' cloud products - Yahoo! Voices
TuHURA Biosciences Completes Merger Transaction with Kintara Therapeutics - Yahoo Finance
State Street Corp's Strategic Acquisition in Beam Therapeutics Inc - Yahoo Finance
Walgreens has more than 100 stores in Indiana. Company plans to shut down 1,200 nationwide - Yahoo News
Dogwood Therapeutics, Inc. Expected to Earn Q3 2024 Earnings of ($1.40) Per Share (NASDAQ:DWTX) - Defense World
Amicus Therapeutics Settles Patent Lawsuit Teva Pharmaceuticals Over Generic Version Of Its Rare Genetic Disorder Drug - Yahoo Finance
AQR Capital Management LLC Has $331,000 Stock Holdings in Scholar Rock Holding Co. (NASDAQ:SRRK) - Defense World
6,661 Shares in Fortune Brands Innovations, Inc. (NYSE:FBIN) Acquired by Sanctuary Advisors LLC - Defense World
After Series Of Trial Setbacks, Sage Therapeutics To Lay Off One-Third Workforce - Yahoo Finance
Outlook Therapeutics® Participates in a Virtual Investor CEO Connect Segment - Yahoo Finance
Power Co. of Canada (TSE:POW) Receives C$43.28 Average Target Price from Brokerages - Defense World
AQR Capital Management LLC Makes New Investment in Canadian Natural Resources Limited (NYSE:CNQ) - Defense World
Tevogen Investors Congratulate on Prestigious Recognition of Pioneering Biopharma Business Model, Breakthrough Innovations, Building Assets Estimated to Exceed $10 Billion - Yahoo Finance
Wells Fargo & Company Increases AptarGroup (NYSE:ATR) Price Target to $185.00 - Defense World
Q4 2025 Earnings Estimate for Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Issued By Zacks Research - Defense World
0.93%
3.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):